Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells

Nature Medicine

Volumn 21, Issue 9, 2015, Pages 1010-1017

  Kim, Il Kyu ^a   Kim, Byung Seok ^a,f   Koh, Choong Hyun ^a   Seok, Jae Won ^b   Park, Jun Seok ^b   Shin, Kwang Soo ^a   Bae, Eun Ah ^b   Lee, Ga Eun ^a   Jeon, Hyewon ^b   Cho, Jaebeom ^a   Jung, Yujin ^a   Han, Daehee ^c   Kwon, Byoung S ^d   Lee, Ho Young ^a   Chung, Yeonseok ^a,e   Kang, Chang Yuil ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Institute for Basic Science   (South Korea)

^d National Cancer Center   (South Korea)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEIN AGONIST ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; GLUCOCORTICOID; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; TNFRSF18 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH9 CELL; TUMOR IMMUNITY; TUMOR REGRESSION; TUMOR REJECTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL DIFFERENTIATION; HELPER CELL; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; GLUCOCORTICOIDS; INTERLEUKIN-9; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; RECEPTORS, INTERLEUKIN-4; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84941022982     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3922     Document Type: Article

References (53)

1. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M. & Chen, L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95-106 (2007).
2. Peggs, K.S., Quezada, S.A., Korman, A.J. & Allison, J.P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18, 206-213 (2006).
3. Maio, M., Di Giacomo, A.M., Robert, C. & Eggermont, A.M. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr. Opin. Oncol. 25, 166-172 (2013).
4. Topalian, S.L., Drake, C.G. & Pardoll, D.M. Targeting the PD-1-B7-H1(PD-L1) pathway to activate antitumor immunity. Curr. Opin. Immunol. 24, 207-212 (2012).
5. Tone, M. et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl. Acad. Sci. USA 100, 15059-15064 (2003).
6. Croft, M. Costimulatory members of the TNFR family: keys to effective T cell immunity? Nat. Rev. Immunol. 3, 609-620 (2003).
7. Schaer, D.A., Murphy, J.T. & Wolchok, J.D. Modulation of GITR for cancer immunotherapy. Curr. Opin. Immunol. 24, 217-224 (2012).
8. Zhou, P., L'Italien, L., Hodges, D. & Schebye, X.M. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced immune activation and tumor immunity in CT26 tumors. J. Immunol. 179, 7365-7375 (2007).
9. Ramirez-Montagut, T. et al. Glucocorticoid-induced TNF receptor family-related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 176, 6434-6442 (2006).
10. Nishikawa, H. et al. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res. 68, 5948-5954 (2008).
11. Zhou, P. et al. Mature B cells are critical to T cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J. Immunother. 33, 789-797 (2010).
12. Ko, K. et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 202, 885-891 (2005).
13. Cohen, A.D. et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5, e10436 (2010).
14. Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y. & Sakaguchi, S. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135-142 (2002).
15. Muranski, P. & Restifo, N.P. Adoptive immunotherapy of cancer using CD4+ T cells. Curr. Opin. Immunol. 21, 200-208 (2009).
16. Dunn, G.P., Koebel, C.M. & Schreiber, R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848 (2006).
17. Kennedy, R. & Celis, E. Multiple roles for CD4+ T cells in antitumor immune responses. Immunol. Rev. 222, 129-144 (2008).
18. Hong, S. et al. Roles of idiotype-specific T cells in myeloma cell growth and survival: TH1 and CTL cells are tumoricidal while TH2 cells promote tumor growth. Cancer Res. 68, 8456-8464 (2008).
19. De Monte, L. et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208, 469-478 (2011).
20. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
21. Purwar, R. et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat. Med. 18, 1248-1253 (2012).
22. Lu, Y. et al. TH9 cells promote antitumor immune responses in vivo. J. Clin. Invest. 122, 4160-4171 (2012).
23. Patel, M. et al. Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis. Eur. J. Immunol. 35, 3581-3590 (2005).
24. Motta, A.C. et al. GITR signaling potentiates airway hyperresponsiveness by enhancing TH2 cell activity in a mouse model of asthma. Respir. Res. 10, 93 (2009).
25. van der Werf, N. et al. TH2 responses to helminth parasites can be therapeutically enhanced by, but are not dependent upon, GITR-GITR ligand costimulation in vivo. J. Immunol. 187, 1411-1420 (2011).
26. Zhu, J., Yamane, H. & Paul, W.E. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28, 445-489 (2010).
27. Veldhoen, M. et al. Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9, 1341-1346 (2008).
28. Dardalhon, V. et al. IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+IL-10+Foxp3- effector T cells. Nat. Immunol. 9, 1347-1355 (2008).
29. Végran, F. et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat. Immunol. 15, 758-766 (2014).
30. Takami, M., Love, R.B. & Iwashima, M. TGF-β converts apoptotic stimuli into the signal for TH9 differentiation. J. Immunol. 188, 4369-4375 (2012).
31. Perumal, N.B. & Kaplan, M.H. Regulating Il9 transcription in T helper cells. Trends Immunol. 32, 146-150 (2011).
32. Chang, H.C. et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11, 527-534 (2010).
33. Staudt, V. et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33, 192-202 (2010).
34. Jabeen, R. et al. TH9 cell development requires a BATF-regulated transcriptional network. J. Clin. Invest. 123, 4641-4653 (2013).
35. Stassen, M. et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-B is decisively involved in the expression of IL-9. J. Immunol. 166, 4391-4398 (2001).
36. Jash, A. et al. Nuclear factor of activated T cells 1 (NFAT1)-induced permissive chromatin modification facilitates nuclear factor-kappaB (NF-kappaB)-mediated interleukin-9 (IL-9) transactivation. J. Biol. Chem. 287, 15445-15457 (2012).
37. Xiao, X. et al. OX40 signaling favors the induction of TH9 cells and airway inflammation. Nat. Immunol. 13, 981-990 (2012).
38. Ruffell, B., Affara, N.I. & Coussens, L.M. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33, 119-126 (2012).
39. Kitajima, M. et al. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells. Cancer Res. 71, 4790-4798 (2011).
40. Hung, K. et al. The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368 (1998).
41. Mattes, J. et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin-and STAT6-dependent process. J. Exp. Med. 197, 387-393 (2003).
42. Stephens, G.L. et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 173, 5008-5020 (2004).
43. Bulliard, Y. et al. Activating Fcreceptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685-1693 (2013).
44. Angkasekwinai, P., Chang, S.H., Thapa, M., Watarai, H. & Dong, C. Regulation of IL-9 expression by IL-25 signaling. Nat. Immunol. 11, 250-256 (2010).
45. Elyaman, W. et al. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity 36, 623-634 (2012).
46. Kaplan, M.H. TH9 cells: differentiation and disease. Immunol. Rev. 252, 104-115 (2013).
47. Yao, W. et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity 38, 360-372 (2013).
48. Lin, G.H., Snell, L.M., Wortzman, M.E., Clouthier, D.L. & Watts, T.H. GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology. J. Immunol. 190, 4627-4639 (2013).
49. Haribhai, D. et al. Regulatory T cells dynamically control the primary immune response to foreign antigen. J. Immunol. 178, 2961-2972 (2007).
50. King, C.G. et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat. Med. 12, 1088-1092 (2006).
51. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012).
52. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early-onset lung cancer in mice. Nature 410, 1111-1116 (2001).
53. Kim, W.J. et al. Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology 119, 421-429 (2006).